BioSpace News Archive

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, will present data from a Phase II placebo-controlled randomized trial at the 2021 American Academy of Neurology Annual Meeting showing that the investigational Bruton’s tyrosine kinase inhibitor evobrutinib significantly reduced blood neurofilament light chain levels, a key biomarker of neuronal damage and inflammation, in patients with multiple sclerosis.

Shenzhen Chipscreen Biosciences announces that it has received Investigational New Drug clearance from the US Food and Drug Administration to proceed with a Phase 1b/2 clinical trial of Chiauranib/CS2164, a potential treatment for multiple oncological indications including Small Cell Lung Cancer, Ovarian Cancer, Liver Cancer, and Breast Cancer, etc.

Elekta AB has held an Extraordinary General Meeting on Friday 16 April 2021. Due to Covid-19, the Meeting was conducted by advance postal vote, without the physical attendance of shareholders, representatives or third parties.A summary of the resolutions taken by the Meeting follows.

PetVivo Holdings, Inc. (OTCQB: PETV) (the “Company”) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets is pleased to announce that Robert J. Folkes has accepted a position with the Company as its new Chief Financial Officer.

Modernizing Medicine today announced that its wholly-owned subsidiary, Modernizing Medicine Podiatry Systems, has acquired TRAKnet and other assets from podiatric electronic health records (EHR) vendor NEMO Health.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that new pooled data from the TEPEZZA® (teprotumumab-trbw) Phase 2 and Phase 3 clinical trials are now published in The Lancet Diabetes & Endocrinology.

Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics (NASDAQ:FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, for $38.00 per share in cash

A large, year-long study has found that among people with COVID-19 who were hospitalized in an intensive care unit, 2% experienced a stroke after they were admitted to the ICU.

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), today announced that the Tiara Transapical system (“Tiara TA”) will be unable to receive a European CE mark under the current Medical Device Directive regulations (“MDD”) ending on May 26, 2021.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Johanna Mercier to its Board of Directors